FDA Chief Counsel Bradshaw's "Practical" Approach Applauded By Barr
This article was originally published in The Pink Sheet Daily
Executive Summary
Barr CEO Bruce Downey is praising FDA Chief Counsel Sheldon Bradshaw's attitude towards issues affecting the generic drug industry
You may also be interested in...
Citizen Petition Reform Under Consideration By FDA
FDA Chief Counsel Bradshaw says options include creating a two-track process – under which ANDAs could be approved while petitions are still under review – or declaring some petitions frivolous.
Barr Launches DDAVP Generic With 180-Day Exclusivity
FDA approves Barr’s ANDA for Sanofi-Aventis’ bed-wetting therapy DDAVP. Approval comes five months after Barr prevailed in a patent dispute with DDAVP manufacturer Ferring.
FDA Chief Counsel Is Assistant Attorney General Bradshaw
Bradshaw brings extensive high-level government service experience to the position as he permanently replaces former Chief Counsel Troy. Deputy Chief Counsel Masoudi has served in the position on an interim basis since Troy’s departure in November.